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Abstract The active component of Wolfberry (Lycium
barbarum), lycium barbarum polysaccharides (LBP), has
been shown to be neuroprotective to retinal ganglion cells
(RGCs) against ocular hypertension (OH). Aiming to study
whether this neuroprotection is mediated via modulating
immune cells in the retina, we used multiphoton confocal
microscopy to investigate morphological changes of micro-
glia in whole-mounted retinas. Retinas under OH displayed
slightly activated microglia. One to 100 mg/kg LBP exerted
the best neuroprotection and elicited moderately activated
microglia in the inner retina with ramified appearance but
thicker and focally enlarged processes. Intravitreous injection
of bacterial endotoxin lipopolysaccharide (LPS) decreased
the survival of RGCs at 4 weeks, and the activated microglia
exhibited amoeboid appearance as fully activated phenotype.
When activation of microglia was attenuated by intravitreous
injection of macrophage/microglia inhibitory factor, protec-
tive effect of 10 mg/kg LBP was attenuated. The results
implicated that neuroprotective effects of LBP were partly
due to modulating the activation of microglia.
Keywords Wolfberry.Glaucoma.Microglia.
Neuroprotection
Introduction
Wolfberry (fruit of Lycium barbarum Linn, in the family
Solanaceae) is known as Fructus Lycii and L. barbarum in
the West and Gouqizi or Kei Tze in Asia. In traditional
Chinese medicine literature, it has been known for
balancing “Yin” and “Yang” in the body, nourishing the
liver and kidney, improving visual acuity for more than
2,500 years [1]. The content of Wolfberry contains about
40% polysaccharides [lycium barbarum polysaccharides
The online version of the original article can be found at http://dx.doi.
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DOI 10.1007/s12177-009-9035-5(LBP)]; therefore, research in Wolfberry often focuses on
these water-soluble fractions. LBP as food supplement
enhances the body defense system by restoring atrophied
thymus in aged subjects and regulates the proliferation and
the immune activity of splenocytes and T cells [2–6]. It has
been shown that LBP can increase phagocytic activity of
macrophages, immune activity of cytotoxic T cells, and
natural killer (NK) cells in cyclophosphamide-treated and
S180-bearing mice [7–9]. LBP increases interleukin-2
(IL-2) receptors on isolated human peripheral lymphocytes
[10]. LBP can be purified into different fractions; glyco-
conjugate LBP3P can increase the expression of messenger
RNA and protein level of IL-2 and tumor necrosis factor-α
(TNF-α) in human peripheral blood mononuclear cells [2]
and increase phagocytosis by macrophage, antibodies
secreted by spleen cells, spleen lymphocyte proliferation,
and cytotoxic T cells activity in S180-bearing mice [9]. Our
previous study reported the neuroprotective effects of LBP
on RGCs in an experimental model of glaucoma [11].
However, it is unclear whether neuroprotection is mediated
via modulating immune cells in the retina, which is our aim
in this study.
Increasing lines of evidence obtained from clinical and
experimental studies strongly suggests an aberrant activity
of the immune system in glaucoma [12, 13]. Microglial
cells are the major immunocompetent cells in the central
nervous system (CNS). It has been reported that microglia
have diverse phenotypes, which secrete beneficial or
destructive factors [14]. Activated microglia have been
considered to be endogenous malefactors in the CNS; they
induce neuronal death by releasing excess cytotoxic factors
such as superoxide [15], nitric oxide, and TNF-α [16–18].
However, increasing lines of evidence have shown that the
protective effects of microglia can be accomplished by
releasing trophic and anti-inflammatory factors [19–24].
Whether microglia exhibit neuroprotective or neurodestruc-
tive effects depends on the disease state or the type of
stimulus. There are increasing lines of evidence in vitro,
showing that itis possible to manipulate the activation state of
microglia so that their activation can be beneficial, i.e.,
protecting rather than destroying neurons [25]. However, it
is difficult to achieve this goal in vivo, especially in a
chronic neurodegenerative model.
A primary objective in this study is to evaluate the
modulation of LBP on retinal microglia and its neuro-
protective effect on survival of RGCs in a chronic ocular
hypertension (OH) model. We studied the morphology of
microglia in OH retina from rats fed with different doses of
LBP. In addition, the effect on the survival of RGCs after
administration of either a microglia activation inhibitor,
macrophage/microglia inhibitory factor (MIF), or microglia
activation stimulator, LPS (bacterial endotoxin lipopolysac-
charide) was evaluated in OH rats.
Materials and methods
Preparation of LBP
The Wolfberry originated from NingXia Huizu Autonomous
Region, the People's Republic of China. The simplified
extraction scheme of LBP from Wolfberry [26] has been
reported by our group. Briefly, the dried wolfberries (10 kg)
were grounded to fine powder and defatted by refluxing with
95% ethanol. The insoluble residue was filtered, air-dried,
and extracted successively with 70° hot water. The concen-
trated extract was incubated with trichloroacetic acid,
extensively dialyzed against running distilled water, concen-
trated, and then precipitated using 95% ethanol. After
centrifugation and several rinses with absolute ethanol and
acetone, the resulting precipitate was vacuum dried at 40° to
yield a brown powder Wolfberry extract–LBP (2 g).
Animal grouping
Sixty-six adult female Sprague–Dawley rats (250–280 g)
were obtained from the Laboratory Animal Unit of the LKS
Faculty of medicine in the University of Hong Kong and
were maintained in a temperature-controlled room with a
12-h light/dark cycle throughout the observation period.
The animals were handled according to the protocol for the
use of animal in research approved by the Committee on
the Use of Live Animals in Teaching and Research of the
University of Hong Kong and the Association for Research
in Vision and Ophthalmology (ARVO, USA) statements for
the use of animals in Ophthalmic and Vision Research.
Prior to measuring intraocular pressure (IOP) or any other
operations, the rats were anesthetized with an intraperitoneal
injection of a ketamine/xylazine mixture (ketamine 80 mg/kg
and xylazine 8 mg/kg; Alfasan, Woerden, Holland). Prior to
every ocular photocoagulation (including IOP measurement,
laser treatment, and intravitreous injection), one drop of
proparacaine hydrochloride (0.5% alcaine, Alcon-Couvreur,
Belgium) was applied to the eyes as a topical anesthetic. After
every ocular manipulation, ophthalmic Tobrex ointment (3%
tobramyxin, Alcon-Couvreur, Belgium) was applied topically
on the eyes to prevent infection. All operations were
performed under an operating microscope (Olympus OME,
Tokyo, Japan).
The animals were divided into 11 groups, and every
group consisted of six rats (Table 1). The LBP powder was
dissolved in 0.01 M sterilized phosphate-buffered saline
(PBS; pH 7.4). Animals were fed daily through a
nasogastric tube with 1 ml of either PBS or different
dosages of LBP, including 1, 10, 100, 1,000 mg/kg. Daily
feeding (groups 2–10) started at 7 days before the first laser
treatment and continued until euthanization of the rats. IOP
was measured before the first laser treatment (as baseline)
128 j ocul biol dis inform (2009) 2:127–136and before killing (postoperative). A total of two laser
photocoagulation was performed at 1-week interval.
Ocular hypertension model
OH was induced in the right eye of each animal using laser
photocoagulation according to our previous publications
[11, 27, 28]. Briefly, the limbal vein and the three radical
episcleral aqueous humor drainage veins (superior nasal,
superior temporal, and inferior temporal) were photocoagu-
lated using an Argon laser (Ultima 2000SE Argon Laser,
Coherent, USA). About 60 laser spots (power, 1,000 mV;
spot size, 50–100 µm; duration, 0.1 s) around the limbal
vein (except the nasal area) and 15–20 laser spots on each
episcleral aqueous humor drainage vein were applied. To
maintain a high IOP, a second laser treatment at the same
settings was applied 7 days later.
Measurement of IOP
IOP was measured with a Tonopen XL tonometer (Mentor®,
Norwell, USA) before the first laser treatment and every
subsequent week until the rats were killed. To avoid diurnal
variation and effect of anesthesia, all IOP measurements were
taken at 10 A.M. and within 15–30 min after administration of
ketamine and xylazine mixture (i.p.). An average of ten
measurements was used to determine the IOP of the eye.
Intravitreous injection
Tuftsin fragment 1–3 acetate salt, also known as MIF, was
purchased from Sigma (St Louis, MO, USA); bacterial
endotoxinlipopolysaccharide(LPS)derivedfromEscherichia
coli O111:B4 was purchased from Calbiochem (La Jolla,
CA, USA). To study the influence of MIF on the survival of
RGCs and microglia activation, immediately after the first
laser treatment, 2 µm of 0.01 M PBS (group 7) or 172 ng of
MIF (2.5 mM) in PBS (group 8) were injected into the
vitreous cavity of the right eye [29] of the 10 mg/kg LBP-fed
group. To demonstrate the fully activated microglia in the
retina, 5 µg of LPS in 2 µl PBS was injected into the vitreous
cavity of the right eye (group 11) immediately after the first
laser treatment. Animals with cataract, intraocular bleeding,
retinal detachment, or non-elevated IOP were excluded from
this study (∼15% of experimental animals).
Retrograde labeling of RGCs
To evaluate the drug effects on RGCs, they were retro-
gradely labeled by applying FG on the surface of superior
colliculus (SC) at 4 days prior to euthanization [30].
Briefly, the rat scalp was cut open in the mid-line, and a
small hole was drilled on the skull on each side of the
sagittal suture. The four edges of SC can be observed
directly under the operation microscope after removing the
overlying cerebral cortex. Then, a thin layer of gelatin
sponge (UpJohn, Kalamazoo, MI, USA) pre-soaked with
6% FG (Fluorochrome, Denver, CO, USA) was placed on
the surface of SC (FG is taken up by the axon terminals of
RGCs and bilaterally transported retrogradely to its somata
in the retina). Then, the scalp was sutured, and an analgesic,
bupreorphine (100 mg/kg), was orally administered for
5 days for pain relief.
Counting of RGCs and statistical analysis
At different time points, the rats were killed with an
overdose of a mixture of ketamine/xylazine after measuring
the IOP. Both eyes were enucleated and post-fixed in 4%
paraformaldehyde for 60 min, then cut horizontally into
Table 1 Experimental grouping
Treatment groups (right eye treated) Survival time after the first laser
photocoagulation
Objectives
2 weeks 4 weeks
No laser 6 (group 1) Normal control
Laser treatment + fed with 0.01 M PBS 6 (group 2) 6 (group 9) Solvent control for drug treatment
Laser treatment + fed with 1 mg/kg LBP 6 (group 3) 6 (group 10) LBP feeding dose –response study
Laser treatment + fed with 10 mg/kg LBP 6 (group 4)
Laser treatment + fed with 100 mg/kg LBP 6 (group 5)
Laser treatment + fed with 1000 mg/kg LBP 6 (group 6)
Laser treatment + fed with 10 mg/kg LBP + i.v.
injection of 0.01 M PBS
6 (group 7) Inhibition of microglia activation by MIF
Laser treatment + fed with 10 mg/kg LBP + i.v.
injection of 172 ng MIF dissolved in 0.01 M PBS
6 (group 8)
Laser treatment + i.v. injection of LPS (50 µg) 6 (group 11) Served as microglia activation control
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intact optic nerves were fixed overnight and processed to
make paraffin blocks. Retinas from the inferior eyecups
were dissected from the underlying sclera, and two cuts
were made to divide the retina into three (nasal, inferior,
and temporal) quadrants. The dissected retinas were then
flattened with the vitreal side up and mounted using
fluorescent mounting medium (Dako, Carpentaria, CA,
USA). The FG-labeled RGCs (FG particles in the cytoplasm)
were visualized at ×40 magnification using a fluorescent
microscope with a UV-385 filter (Nikon, Kawasaki, Japan).
The photos of RGCs were taken (200×200 µm
2/microscope
field) with each 500-µm separation along the median line of
each quadrant (eight microscopic fields/quadrant) starting
from the optic disc to the peripheral border of the retina.
After counting of the RGCs with the aid of a computer
software developed by us (manuscript in preparation), the
results were manually double checked by a person who was
blinded to the grouping. The average density of RGCs was
calculated for the entire retina.
To evaluate different effects of various treatments,
changes in the density of FG-labeled RGCs were expressed
as a percentage loss of FG-labeled RGCs by comparing the
laser-treated right eye and normal control eye:
Density of RGCs in the normal eye – Density of RGCs in the right eye with OH
Density of RGCs in the normal eye
 
 100%
The percentage loss of FG-labeled RGCs in different
treatment groups was compared using one-way analysis
of variance followed by a post hoc Tukey multiple
comparison test (SigmaStat®, statistical significance is
noted as p<0.05).
Immunohistochemistry of microglia in retinal sections
Retinal sections from different groups were handled at the
same time for each primary antibody to avoid bench to
bench variation. Four micrometer cross-retinal sections
with intact optic nerves were used to detect OX42
immunoreactivity. The sections were deparaffinized and
boiled in citric acid buffer (0.01 M, pH 6.0, 15 min).
Catalytic enhancement was performed by incubation in 1%
H2O2 for 15 min. Following washing and blocking, retinal
sections were incubated with mouse anti-rat monocolonal
OX42 primary antibody (1:25, Pharmingen, California,
USA) overnight at 4 C. After further washing, retinal
sections were incubated with biotinylated goat and mouse
secondary antibody (Molecular Probe) at room temperature
for 1 h. Then, the sections were washed with TBS and
incubated with avidin–biotin complex (Vector Lab, USA)
for 1 h. The slides were washed in TBS twice and once in
imidozole-acetate buffer (175 mM acetate, 10 mM imidazole,
pH 7.2), for 10 min each. The sections were further incubated
with 3,3-diaminobenzidine (DAB; 10 mM NiSO4,1 2 5m M
acetate, 10 mM imidozole, 0.03% DAB, 0.003%H2O2, pH
7.2) for 10 min. The sections were mounted with Permount
medium. OX42-immunoreactive signals were observed
under a light microscope. Images were captured using
the Spot-Advance Digital system (Spot RT; Diagnostic
Instruments, Sciscope Instrument Companies, USA). The
specificity of the antibody was tested by omission of the
primary antibody.
Immunohistochemistry of microglia in flat-mounted retina
In the 4-week study (groups 9, 10, and 11), the flat-
mounted retinas were carefully removed from the slides and
rehydrated in 0.1 M PB using 48-well plate. There were six
rats in each group, and three retinas from each group were
used for the flat-mounted immunohistochemical study. The
retinas were washed in 0.1 M PB with constant shaking at
4 C overnight to wash out the fluorescent mounting
medium. Then, they were blocked with 10% normal goat
serum in 0.1 M PB containing 1% Triton X-100 for about
2 h at 4 C. After three washings of ice-cold 0.1 M PB, the
retinas were incubated with ionized calcium adaptive
molecular 1 (iba-1) primary antibody (1:800; Wako
Chemicals USA, Richmond, USA) for 3 days at 4 C. To
visualize microglia, the retinas were incubated with Alexa-
594 fluorescent-conjugated secondary antibody (1:800;
Molecular Probe, USA) for 1 h at room temperature. To
visualize different layers of the retina, they were further
incubated with 0.2% diamidino-2-phenylindole (DAPI) for
1 h at room temperature. In between each incubation step,
there were three turns of 0.1 M PB washing for 10 min
each. Finally, the retinas were flat-mounted using fluorescent
mounting medium with the vitreal side facing upward.
Under fluorescent microscope, the iba-1 signal was
checked throughout the retina, and there was no regional
difference observed. Therefore, one representative retinal
area of 230×230 µm
2 at about 2,500 µm from the optic
disc of each retina was scanned at ×40 magnification using
a LSM-510Meta multiphoton confocal microscope (Carl
Zeiss, Jena, Germany). All the images were taken under
exactly the same excitation attenuation to avoid bias on the
judgment of the immunoreactivity. The gain level for all
groups was identical in order to demonstrate the best
resolution of the microglia in the normal control group.
130 j ocul biol dis inform (2009) 2:127–136Guided by the morphology of DAPI-stained nuclei,
scanning started from the surface of inner-limiting mem-
brane to the outer nuclear layer. The Z interval was 1 µm
among different focal planes, and depending on the retinal
thickness, 80 planes would be scanned for each retina. On
average, the scanning time for each retina was around 1 h.
VerticalfigureconfiguredbytheLSMsoftwareillustratedthat
most of the microglia were in the inner retina (from inner-
limiting membrane to the outer mostlayer of the inner nuclear
layer). Stacked images of different focal planes in the inner
retinawerecreatedusingtheLSM softwareinorder todisplay
the entire microglia cell body and their processes. To further
demonstratethemorphologyofdifferentstatusesofmicroglia,
representative single cells were chosen from the ×40
magnification region and then re-scanned under ×63 magni-
fication. The scan started from the upper border of the
processes to the soma and then to the lower border of the
processes; the Z-interval was also 1 µm.
Results
Laser photocoagulation increased the IOP of the right eyes
(OH eyes) about 1.7 times compared to the contralateral
control eyes (23.4 vs. 13.9 mmHg). Oral feeding of PBS or
various doses of LBP did not alter the level of IOP in all
animals.
Monoclonal OX42 antibody that recognizes the expres-
sion of complement receptor 3 on the microglia was used to
detect all statuses of microglia (from resting to fully activated
status) in the retinal sections. In normal retinas (group 1),
only processes-like signals of OX42 without identifiable
perikarya or cell body were observed (Fig. 1a). At 2 weeks
after the first laser-induced OH, there was a loss of 17% of
RGCs in the PBS-fed rats (group 2) [11]. OX42-positive
microglia were observed in the inner retina [including
ganglion cell layer (GCL), inner plexiform layer, and inner
nuclear layer (INL)] with ramified morphology (Fig. 1b).
These cells were slightly activated and exhibited small
perikarya with long thin branching processes that were
detectable in 4-μm sections. We repeated the LBP-fed
doses that previously showed significant protection on
the survival of RGCs (groups 3, 4, and 5). The loss of
RGCs was 1% in 1 mg/kg, 0% in 10 mg/kg, and 2.4% in
100 mg/kg [11]. In LBP-fed rats, both the number and
intensity of OX42-positive microglia increased in parallel
with the increase in dosages of LBP feeding. In animals
with administration of LBP from 1 to 100 mg/kg, the
majority of microglia in the retina of groups 3–5 was in
ramified morphology (Fig 1c–e). However, the processes
became thicker, and the branching increased compared with
the PBS group. The maximum radial extent of the cell
(soma axis + longest processes) was about 50 μm. We
defined this as a moderate activation status. In 1,000 mg/kg
group (group 6), there was much less protection on RGCs
as shown by us previously [11]. In the retinas of this group
of animals, most of the OX42 immunoreactive positive
microglia was intensely stained, showing the fully activated
status with amoeboid shape (Fig. 1f). The perikaya were
enlarged, showing coarse and swollen appearance. The
Fig. 1 Distribution and
morphology of OX42-
immunoreactive microglia in
cross-retinal sections. In normal
retina (a), only processes
without cell body showing
OX42- immunoreactive can be
detected. In the OH retina from
the PBS feeding group (b),
ramified microglia can be
detected. In the OH retina of
animals receiving different
doses of the Wolfberry extract,
1 mg/kg (c), 10 mg/kg (d) and
100 mg/kg (e), there was an
increase both in the number and
immune intensity of OX42
microglia. In the 1000 mg/kg
group (f), increased number of
fully activated microglia was
detected. They contained coarse
and swollen perikarya that
connected with thick processes.
Scale bar is 50 μm
j ocul biol dis inform (2009) 2:127–136 131processes were shortened and thicken with little branches.
The maximum radial extent of these cells (soma axis +
longest processes) was less than 30 μm. In addition, the
entire area of the OX42 immunoreactive positive cells
including the processes was markedly reduced. Thus, there
seems to be a dose-related correlation of microglia
activation status with neuroprotective effect of LBP. A
moderate activation of microglia may be correlated with the
neuroprotective effect of LBP in 1–100 mg/kg groups.
However, in the 1,000 mg/kg group, less neuroprotection is
linked to fully activated status of microglia.
In order to further illustrate the detailed morphology of
the various statuses of microglia, a multiphoton laser-
scanning microscope was used to reconstruct the entire
microglia on whole-mounted retina. For this purpose,
polyclonal ionized calcium adaptive molecular 1 (iba-1)
primary antibody was used. The iba-1 protein is specifically
localized in microglia and is not found in neurons,
astrocytes, or oligodendroglia [31, 32]. Expression of iba-1
is enhanced when microglia are activated [33]. The retinas
were first flat-mounted for counting of RGCs and then
r e f l o a t e dt og ot h r o u g ht h ei m m u n o h i s t o c h e m i c a ls t a i n i n g .
The morphology of microglia was investigated using multi-
photon laser-scanning microscope (LSM-510Meta, Zeiss).
At 4 weeks after the first laser photocoagulation,
confocal images by stacking all Z layers in the inner retina
(from the nerve fiber layer to the INL) showed the slightly
activated microglia in the PBS-fed group (group 9); they
displayed small perikarya and two or more thin branching
processes, which were longer than the soma diameter
(Fig 2a). In 1 mg/kg LBP-fed rats, microglia displayed
increased iba-1 immunoreactivity in both the soma and
processes. There was enlargement of the soma and regional
thickening of the processes (Fig 2b). At 4 weeks, LBP
significantly reduced the loss of FG-labeled cell from
21.1% (PBS fed) to 6.6% (as previously reported [11]).
Therefore, consistent with the 2-week observation after
administration of LBP in OH rats, moderately activated
microglia were linked to neuroprotection of RGCs in OH rats.
Will the neuroprotective effect be affected if microglia
are fully activated? To test the effect of fully activated
microgliaintheretinaunderOH,bacterialendotoxinLPSwas
intravitreously injected immediately after the first laser. The
effect on the survival of RGCs was observed at 4 weeks time
point. Intravitreous injection of LPS significantly increased
the loss of RGCs from 21.1±1.5% (PBS fed) to 28.1±1.9%
(p<0.05, Fig. 3b). Neither the neuroprotective effect of LBP
nor the neurodestructive effect of LPS on the survival of
RGCs was linked to any changes of IOP after the laser
treatment (Fig. 3a).
The morphology of one of the representative microglia at
resting, moderate, and fully activated status was scanned at
×63 magnification. In normal retina, resting microglia
(diameter, ∼50 μm) exhibited ramified shape with small
nuclei and long thin processes and were located in the inner
retina with almost no overlapping of processes (Fig. 4a). At
4 weeks of OH, microglia in the LBP-fed rats (Fig 4b)
showed a moderatively activated morphology with in-
creased iba-1 immunoreactivity in the soma and processes.
The processes were shortened with focal enlargement com-
pared with resting microglia. Intravitreous injection of LPS at
5 μg greatly alerted microglia from a resting state to a fully
activated state in the hypertensive eyes; immunoreactivity of
iba-1 in the microglia was dramatically increased. They
displayed enlarged nucleiand significantly thicker and shorter
processes (Fig. 4c).
a b
Fig. 2 Morphology of iba-1 immunoreactive microglia in flat-
mounted retinas at four weeks after the first laser photocoagulation.
Confocal images by stacking all Z layers in the inner retina (from the
nerve fiber layer to the inner nuclear layer) showed that morphology
of the resting microglia in the PBS-fed group displayed small
perikarya and two or more thin branching processes, which are longer
than the soma diameter (a). In LBP-fed rats, the microglia displayed
increased iba-1 immunoreactivity in both the soma and processes.
There was enlargement of the soma and regional thickening of the
processes (b). Scale bar is 20 μm
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microglia have the neuroprotective effects, activation of
microglia was attenuated by using intravitreous injection
of MIF. Compared with intravitreous injection of PBS
(1.8±2.5%), there was a greater loss of RGCs (9.7±1.1%,
p=0.026) after the intravitreous injection of MIF (Fig. 5b)
in the LBP-fed rats. Intravitreous injection of PBS did not
affect the survival of RGCs in LBP-fed rats following
induction of OH. The elevated IOP was not altered by
intravitreous injection of MIF or PBS (Fig. 5a).
Discussion
Our results suggest that the neuroprotective effects of LBP
are partly due to the modulation of activation status of
microglia. Concomitant with neuroprotective effect of LBP
(1–100 mg/kg), microglia in the retina are moderately
activated. Confocal image of the moderately activated
microglia in the inner retina exhibits ramified morphology
with thicker and focally enlarged processes, which are
different from the resting microglia. This kind of morphology
is different from what we can observe by using LPS to elicit
fully activated microglia. Appearance of this form of micro-
glia is correlated with the neuroprotection of LBP because the
use of MIF to inhibit activation of microglia can attenuate the
neuroprotective effect of LBP.
Microglial cells are considered to be resident immune cells
in the CNS. In the normal mature brain, “resting” microglia
constantly extend their processes, with extention and retrac-
tion of the processes as well as motile filopodium-like
a
b c
Fig. 4 Z-stacked confocal images in the inner retina showing three
types of representative microglial phenotype. In the normal retina (a),
the resting microglia showed ramified morphology with small
perikarya and three highly branching thin processes. At 4 weeks
under the ocular hypertension, microglia in the LBP-fed rats (b)
showed increased iba-1 immunoreactivity in the soma and certain
enlarged long processes. The processes were shortened compared to
resting microglia with focal enlargement. In the OH retina at 4 weeks
following intravitreal injection of LPS (c), microglia was fully
activated, showing swollen perikarya and several thick processes with
size similar to the soma diameter. Scale bar is 5 µm
right right right left left left
PBS LBP LPS
PBS LBP LPS
a
b
# # #
Fig. 3 Profile of the intraocular pressure (IOP) (a) and loss of FG-
labeled RGCs in the OH retinas (b) from PBS, LBP-fed rats or LPS
intraocular injection at 4 weeks after the first laser treatment. IOP of
the right eye was significantly
(#p<0.05) elevated to about 1.5-fold to
that of the contralateral left control eye (a). There was no significant
difference in the eyes among PBS-fed, LBP-fed, and LPS intraocular
injection groups. Compared with PBS-fed control (b), 1 mg/kg LBP
daily feeding significantly reduced the loss of RGCs at four weeks
(**p<0.001), while LPS intraocular injection increased the loss of
RGCs (*p<0.05). Error bar represents SEM. The LBP result was
reported previously [11] and reproduced here for comparison
j ocul biol dis inform (2009) 2:127–136 133protrusions [34, 35]. They are appropriately named “surveil-
lance” microglia because they actively search for and detect
signals in their neighboring environment [36]. Activation of
microglia has been considered as a stepwise transformation
from resting state (ramified morphology) to activated state
(amoeboid morphology) in response to pathological stimuli.
Based on new findings from in vivo imaging [34, 35],
activation of microglia should no longer be considered to be
an all or none or one-step event. As pointed out by Hanisch
and Kettenmann, the transition between resting and activated
states should be considered to be a change in their functions
[36]. Activation of microglial cells can result in different
morphologies with diverse functions. Engagement of micro-
glia can be either neuroprotective or neurotoxic, resulting in
containment or aggravation of disease progression [14, 36].
Our study provides in vivo evidence that a moderately
activated microglial morphology correlates with the survival
of neurons in ocular hypertensive retina.
The important role of moderately activated microglia was
further strengthened by using MIF in our experiment. Both in
vitro and in vivo experiments previously show that MIF
directly inhibits the activation of microglia/macrophages [37–
39]a n dh a sn od i r e c te f f e c to nn e u r o nv i a b i l i t y[ 40]. In our
experiment, the use of MIF attenuated the neuroprotective
effect of LBP. The results suggest that activation of microglia
at least partially contributed to the neuroprotective effect of
LBP.
LPS has long been considered to be a potent stimulus for
microglia. Intravitreous injection of LPS decreased the
survival of RGCs at 4 weeks and stimulated microglia to
amoeboid morphology, which is consistent with the
morphology of activated microglia described previously
(Fig. 4c). The increased death of RGCs should not be due
to direct neurotoxic effect of LPS, as it has been shown that
LPS does not exert direct neurotoxicity on neurons [41].
Therefore, fully activated microglia are neurodestructive
rather than neuroprotective.
The modulation of body immunity is often one of the
first indicators to access how a Chinese medicine improves
our overall body health [42–44]. It has been shown that
LBP can increase phagocytic activity of macrophages,
antibodies secreted by spleen cells, lymphocyte prolifera-
tion in spleen, and activity of cytotoxic T cells [7–9]. In
vitro, LBP has been demonstrated to induce maturation of
murine bone marrow-derived dendritic cells to secrete
IL-12 p40 and increase the expression of membrane
markers I-A/I-E and CD11c [45]. This study provides the
first in vivo evidence that neuroprotective effects of LBP in
a rat glaucoma model may be partly due to the modulation
of microglia in the retina.
There is also a possibility that LBP provides direct
protection of the RGCs against OH. LBP has been shown
to improve cognitive functions by enhancing the spontane-
ous electrical activity of the hippocampus in vivo [46]. In
view of the direct cytoprotective and anti-aging effects, it
has been shown that LBP counteracts β-amyloid peptide
toxicity in primary neuronal cell culture [26, 47–49]. In
addition to its anti-oxidant effects [50, 51], LBP can inhibit
two key pro-apoptotic signaling pathways (JNK and PKR)
in Aβ peptide neurotoxicity [47, 48, 52, 53]. Recently, a
new arabino-galactan-protein (LBP-III) isolated from LBP
was reported to attenuate the Aβ peptide-triggered caspase-
3-like activity and the phosphorylation of PKR [26].
Therefore, pro-apoptotic signaling pathways, including
PKR, JNK and caspase-3 like activity, should also be
evaluated in the LBP neuroprotection against apoptotic
RGCs deaths in experimental glaucoma.
According to the theory of Chinese medicine, Wolfberry
(L. barbarum) may modulate the energy flow known as
“Qi” in our body, meaning that it can modulate one organ
indirectly by affecting other organs. For example, 10 mg/kg
LBP can significantly reduce blood glucose, nitric oxide,
and malondoaldehyde levels in streptozotocin-induced
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Fig. 5 Profile of the intraocular pressure (IOP) (a) and loss of FG-
labeled RGCs in the OH rat retinas fed with 10 mg/kg LBP with
different intravitreous injections (b). At 2 weeks after the first laser,
IOP at the right eyes of all rats was elevated to about 1.5 times to the
contralateral control left eyes. There was no difference in the OH eyes
among different groups (a). Neuroprotection from Wolfberry extract-
LBP on RGCs was not sustained after intravitreous injection of MIF
when compared with the intravitreous injection of PBS (
#p=0.026)
134 j ocul biol dis inform (2009) 2:127–136diabetic rats [54]. Therefore, in our previous study
reporting neuroprotective effects of LBP on the survival
of RGCs against OH, vital organs were also collected to
comprehensively study LBP biological mechanisms in
other organ systems. We hope to use this experimental
glaucoma model as an example to illustrate both the
“direct” and possible “indirect” effects of Wolfberry as
proposed by Chang and So [1]. These results may guide us
on how to make use of Wolfberry for therapeutic
intervention of glaucoma in the future.
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